Sonoma Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview

Reuters

Aug 05

Sonoma Pharmaceuticals Inc <snoa.oq> expected to post a loss of 51 cents a share - Earnings Preview </snoa.oq>

Sonoma Pharmaceuticals Inc SNOA.OQ SNOA.O is expected to show a rise in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
The Boulder Colorado-based company is expected to report a 19.4% increase in revenue to $4.05 million from $3.39 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Sonoma Pharmaceuticals Inc is for a loss of 51 cents per share.
The one available analyst rating on the shares is "strong buy".
The average consensus recommendation for the pharmaceuticals peer group is also "Strong Buy".
Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 79.2% above its last closing price of $3.09

This summary was machine generated August 4 at 21:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557372332"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557372332\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557372332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 05:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557372332","market":"nz","top_or_hot":-1,"title":"Sonoma Pharmaceuticals Inc  expected to post a loss of 51 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sonoma Pharmaceuticals Inc <snoa.oq> expected to post a loss of 51 cents a share - Earnings Preview </snoa.oq></title></head><body><ul><li><p>Sonoma Pharmaceuticals Inc <span>SNOA.OQ</span> <span>SNOA.O</span> is expected to  show a rise in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025</p></li><li><p>The Boulder Colorado-based  company is expected to report a 19.4% increase in revenue to $4.05 million from $3.39 million a year ago, according to the estimate from one analyst, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Sonoma Pharmaceuticals Inc is for a loss of 51 cents per share. </p></li><li><p>The one available analyst rating on the shares is \"strong buy\".  </p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is also \"Strong Buy\".</p></li><li><p><a href=\"https://laohu8.com/S/WSCO\">Wall Street</a>'s median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 79.2% above its last closing price of $3.09</p></li></ul><p>This summary was machine generated August 4 at 21:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sonoma Pharmaceuticals Inc  expected to post a loss of 51 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSonoma Pharmaceuticals Inc  expected to post a loss of 51 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-05 05:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sonoma Pharmaceuticals Inc <snoa.oq> expected to post a loss of 51 cents a share - Earnings Preview </snoa.oq></title></head><body><ul><li><p>Sonoma Pharmaceuticals Inc <span>SNOA.OQ</span> <span>SNOA.O</span> is expected to  show a rise in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025</p></li><li><p>The Boulder Colorado-based  company is expected to report a 19.4% increase in revenue to $4.05 million from $3.39 million a year ago, according to the estimate from one analyst, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Sonoma Pharmaceuticals Inc is for a loss of 51 cents per share. </p></li><li><p>The one available analyst rating on the shares is \"strong buy\".  </p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is also \"Strong Buy\".</p></li><li><p><a href=\"https://laohu8.com/S/WSCO\">Wall Street</a>'s median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 79.2% above its last closing price of $3.09</p></li></ul><p>This summary was machine generated August 4 at 21:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNOA","symbol_name":"Sonoma Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nL8N3TW2JM:1","article_id":"2557372332","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557372332","pubTimestamp":1754343784,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sonoma Pharmaceuticals Inc  expected to post a loss of51cents a share - Earnings Preview Sonoma Pharmaceuticals Inc SNOA.OQ SNOA.O is expected to  show a rise in quarterly revenue when it reports  res","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SNOA":"Sonoma Pharmaceuticals, Inc."},"translate_title":"Sonoma Pharmaceuticals Inc预计每股亏损51美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNOA":0.9},"content_text":"Sonoma Pharmaceuticals Inc  expected to post a loss of 51 cents a share - Earnings Preview Sonoma Pharmaceuticals Inc SNOA.OQ SNOA.O is expected to  show a rise in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025The Boulder Colorado-based  company is expected to report a 19.4% increase in revenue to $4.05 million from $3.39 million a year ago, according to the estimate from one analyst, based on LSEG data.LSEG's mean analyst estimate for Sonoma Pharmaceuticals Inc is for a loss of 51 cents per share. The one available analyst rating on the shares is \"strong buy\".  The average consensus recommendation for the pharmaceuticals peer group is also \"Strong Buy\".Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 79.2% above its last closing price of $3.09This summary was machine generated August 4 at 21:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}